Free Trial
NASDAQ:HOOK

Hookipa Pharma Q3 2023 Earnings Report

Hookipa Pharma logo
$0.84 +0.06 (+7.71%)
As of 04/24/2025 04:00 PM Eastern

Hookipa Pharma EPS Results

Actual EPS
-$1.70
Consensus EPS
-$2.30
Beat/Miss
Beat by +$0.60
One Year Ago EPS
N/A

Hookipa Pharma Revenue Results

Actual Revenue
$6.87 million
Expected Revenue
$3.39 million
Beat/Miss
Beat by +$3.48 million
YoY Revenue Growth
N/A

Hookipa Pharma Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Hookipa Pharma's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Monday, May 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Hookipa Pharma Earnings Headlines

Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Hookipa Pharma Drops Poolbeg Takeover Bid
See More Hookipa Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hookipa Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hookipa Pharma and other key companies, straight to your email.

About Hookipa Pharma

Hookipa Pharma (NASDAQ:HOOK)., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

View Hookipa Pharma Profile

More Earnings Resources from MarketBeat